AMRX Amneal Pharmaceuticals Inc
Price (delayed)
$8.23
Market cap
$2.55B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.38
Enterprise value
$5.03B
Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products. The Company has operations in
Highlights
AMRX's EPS has soared by 56% since the previous quarter and by 21% year-on-year
The company's gross profit rose by 24% YoY and by 8% QoQ
The company's net income fell by 39% YoY but it rose by 37% QoQ
AMRX's quick ratio is down by 6% YoY but it is up by 3.9% from the previous quarter
Amneal Pharmaceuticals's equity has decreased by 17% QoQ
Key stats
What are the main financial stats of AMRX
Market
Valuations
Earnings
Shares outstanding
309.97M
Market cap
$2.55B
Enterprise value
$5.03B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.91
EV/EBIT
31.3
EV/EBITDA
12.67
EV/Sales
1.8
Revenue
$2.79B
Gross profit
$1.02B
Operating income
$248.4M
Net income
-$116.89M
EBIT
$160.57M
EBITDA
$396.76M
Free cash flow
$234.76M
Per share
Balance sheet
Liquidity
EPS
-$0.38
EPS diluted
-$0.38
Free cash flow per share
$0.76
Book value per share
-$0.35
Revenue per share
$9.04
TBVPS
$7.03
Total assets
$3.5B
Total liabilities
$3.61B
Debt
$2.59B
Equity
-$109.27M
Working capital
$458.04M
Debt to equity
-23.73
Current ratio
1.41
Quick ratio
0.79
Net debt/EBITDA
6.24
Margins
Efficiency
Dividend
EBITDA margin
14.2%
Gross margin
36.5%
Net margin
-4.2%
Operating margin
8.9%
Return on assets
-3.4%
Return on equity
N/A
Return on invested capital
4.4%
Return on capital employed
6.8%
Return on sales
5.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AMRX stock price
How has the Amneal Pharmaceuticals stock price performed over time
Intraday
-1.79%
1 week
-3.52%
1 month
-5.07%
1 year
36.03%
YTD
3.91%
QTD
-1.79%
Financial performance
How have Amneal Pharmaceuticals's revenue and profit performed over time
Revenue
$2.79B
Gross profit
$1.02B
Operating income
$248.4M
Net income
-$116.89M
Gross margin
36.5%
Net margin
-4.2%
The company's operating income rose by 44% QoQ and by 31% YoY
The company's net income fell by 39% YoY but it rose by 37% QoQ
AMRX's net margin is up by 39% since the previous quarter but it is down by 20% year-on-year
The operating margin is up by 37% since the previous quarter and by 13% year-on-year
Growth
What is Amneal Pharmaceuticals's growth rate over time
Valuation
What is Amneal Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
0.91
EV/EBIT
31.3
EV/EBITDA
12.67
EV/Sales
1.8
AMRX's EPS has soared by 56% since the previous quarter and by 21% year-on-year
Amneal Pharmaceuticals's equity has decreased by 17% QoQ
The price to sales (P/S) is 133% higher than the 5-year quarterly average of 0.4 and 16% higher than the last 4 quarters average of 0.8
AMRX's revenue is up by 17% year-on-year and by 4.2% since the previous quarter
Efficiency
How efficient is Amneal Pharmaceuticals business performance
AMRX's ROIC has soared by 69% from the previous quarter and by 29% YoY
AMRX's ROS has soared by 58% since the previous quarter
The company's return on assets fell by 48% YoY but it rose by 36% QoQ
Dividends
What is AMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AMRX.
Financial health
How did Amneal Pharmaceuticals financials performed over time
AMRX's total assets is 3% smaller than its total liabilities
The company's current ratio fell by 13% YoY but it rose by 2.2% QoQ
AMRX's quick ratio is down by 6% YoY but it is up by 3.9% from the previous quarter
The company's debt to equity has shrunk by 117% YoY but it rose by 16% QoQ
Amneal Pharmaceuticals's equity has decreased by 17% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.